At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cell Mediated Immunity Against RSV and Influenza in a Human Experimental Challenge
In Brief
A clinical study evaluating RSV A Memphis 37, Influenza A/California/04/2009-likw (H1N1), and 1 other intervention for Respiratory Syncytial Virus Infections and Influenza, Human. Completed, enrolled 75 participants across 1 site.
Detailed Summary
Respiratory viruses including influenza and respiratory syncytial virus (RSV) are among the most important causes of severe disease globally, infecting everyone repeatedly throughout life. Understanding of how to prevent infection is incomplete but boosting immunity with vaccines remains the best strategy. T cells have been shown in animals to be essential for clearing respiratory viral infection and are likely to be helpful if stimulated by vaccines. However, where these cells originate from and how they develop in the human lung are still unclear. The investigators will inoculate volunteers with influenza or RSV to examine the relationship between T cells in their blood and lungs and the outcome of infection. By tracking these specialised cells, the investigators aim to develop a better understanding of how they are generated in order to harness them with future vaccines.
Study Details
Timeline
Interventions
Good Manufacturing Practices-certified RSV Memphis 37 10(4) PFU in 1 mL 25% sucrose/DMEM delivered by intranasal drops
Good Manufacturing Practices-certified Influenza A/California/04/09 3.5x10\^6 TCID50 in 1 mL in DPBS delivered by intranasal drops
Good Manufacturing Practices-certified Influenza A/Belgium/4217/2015 (H3N2) 3.5x10\^6 TCID50 in 1 mL in DPBS delivered by intranasal drops